{"id":"duo-therapy-with-sildenafil-bosentan","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Flushing"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Liver enzyme elevation"},{"rate":null,"effect":"Fluid retention"},{"rate":null,"effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sildenafil inhibits phosphodiesterase-5, increasing cyclic GMP and promoting vasodilation. Bosentan is an endothelin receptor antagonist that blocks vasoconstriction mediated by endothelin-1. Together, these agents work synergistically to reduce pulmonary vascular resistance and improve hemodynamics in pulmonary hypertension.","oneSentence":"This combination therapy dilates pulmonary blood vessels through dual inhibition of phosphodiesterase-5 and endothelin-1 receptor signaling.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:16.133Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary arterial hypertension"}]},"trialDetails":[{"nctId":"NCT04039464","phase":"PHASE3","title":"Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2022-08-01","conditions":"Pediatric Pulmonary Hypertension","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dual therapy with Revatio and Tracleer"],"phase":"phase_3","status":"active","brandName":"Duo-Therapy with Sildenafil + Bosentan","genericName":"Duo-Therapy with Sildenafil + Bosentan","companyName":"Johns Hopkins University","companyId":"johns-hopkins-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy dilates pulmonary blood vessels through dual inhibition of phosphodiesterase-5 and endothelin-1 receptor signaling. Used for Pulmonary arterial hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}